Free STEP1 Exam Braindumps
Step1 Questions 372–376 (page: 76)

Updated On: 9-Feb-2026

Which of the following clotting factors forms an active complex with tissue factor (factor III) to initiate the extrinsic clotting cascade?

  1. factor I (fibrinogen)
  2. factor VII (proconvertin)
  3. factor VIII
  4. factor IX
  5. protein S

Answer(s): B

Explanation:

The extrinsic pathway (see below figure)

is initiated at the site of injury in response to the release of tissue factor (factor III). Tissue factor is a cofactor in the factor VIIa-catalyzed (lower case alpha refers to the active form of the coagulation factors) activation of factor X. The formation of a complex between factor VIIa and tissue factor is believed to be a principal step in the overall clotting cascade. Evidence for this stems from the fact that persons with hereditary deficiencies in the components of the contact phase of the intrinsic pathway do not exhibit clotting problems. Factor VIIa, a gamma-glutamate (gla residue) containing serine protease, cleaves factor X to factor Xa in a manner identical to that of factor IXa of the intrinsic pathway. The activation of factor VII occurs through the action of thrombin or factor XA. The ability of factor Xa to activate factor VII creates a link between the intrinsic and extrinsic pathways. An additional link between the two pathways exists through the ability of tissue factor and factor VIIa to activate factor IX. Fibrinogen (choice A) is cleaved by thrombin (factor IIa), yielding fibrin monomers that polymerize to form a fibrin clot. The activation of factor VIII (choice C) to factor VIIIa occurs in the presence of minute quantities of thrombin. Factor VIIIa is required for the activation of factor X, which represents the convergence of the intrinsic and extrinsic pathways. The activation of factor X to Xa requires assemblage of the tenase complex (C and factors VIIIa, IXa, and X) on the surface of activated platelets. As the concentration of thrombin increases, factor VIIIa is ultimately cleaved by thrombin and inactivated. This dual action of thrombin on factor VIII acts to limit the extent of tenase complex formation, and thus the extent of the coagulation cascade. Factor IX choice D) functions only in the intrinsic cascade. When activated, factor IXa aids in the activation of factor X by functioning in the tenase complex as described above. Protein S (choice E) is a cofactor for protein C. Protein C is itself activated by thrombin and when active, cleaves factors VIIIa and Va, thus limiting the extent of the coagulation cascade.



Many effective anticancer drugs function as such by interfering with processes of DNA replication. The drug, doxorubicin, is useful in the treatment of lymphomas and breast cancers because of its ability to interfere with which of the following enzyme activities?

  1. DNA ligase
  2. DNA polymerase-alpha
  3. primase
  4. topoisomerase II
  5. uracil N-glycosylase

Answer(s): D

Explanation:

Doxorubicin is a drug of the class that functions by interfering with topoisomerases. In particular, doxorubicin inhibits topoisomerase II. During the process of DNA replication , the two strands of the DNA helix are separated. As the replication fork progresses toward sites of chromosomal attachment to the scaffold, there is an increase in the torsional stress on the helix due to supercoiling. These torsional stresses are relieved by the action of topoisomerases that introduce nicks into the DNA, which allows the strands to unwind the supercoils. Topoisomerase I introduces single-strand nicks, whereas topoisomerase II introduces double-strand nicks. Interference with the action of topoisomerases would thus impair the rate of DNA replication and this would be detrimental for rapidly proliferating cells such as cancer. Doxorubicin does not affect the activity of any of the other enzymes (choices AC, E).



Exhibit:

Please refer to the exhibit.
When fatty acids with odd numbers of carbon atoms are oxidized in the beta-oxidation pathway the final product is 1 mole of acetyl- CoA and 1 mole of the 3-carbon molecule, propionyl-CoA. In order to use the propionyl carbons, the molecule is carboxylated and converted ultimately to succinyl-CoA and fed into the TCA cycle. Which of the following represents the vitamin cofactor required in one of the steps of this conversion?

  1. A
  2. B
  3. C
  4. D
  5. E

Answer(s): A

Explanation:

Propionyl-CoA is converted to succinyl- CoAin a series of reactions using three different enzymes. It is first carboxylated in an ATPdependent reaction catalyzed by propionyl- CoA carboxylase, an enzyme that requires biotin as a cofactor. The product of the first reaction, d-methylmalonyl-CoA is then converted to l- methylmalonyl-CoA by methylmalonyl-CoA racemase. Finally, methylmalonyl-CoA is converted to succinyl- CoA by the cobalaminrequiring enzyme, methylmalonyl-CoA mutase. None of the other vitamins (choice B, C, D, and E) are required in this pathway.



Mutant genes that affect several organ systems and bodily functions frequently show variable expressivity, a phenomenon referred to as phenotypic variation. The most striking example of phenotypic variability is manifest in an autosomal- dominant condition characterized by the appearance of café au lait spots on the skin and cutaneous and subcutaneous neurofibromas. These symptoms are associated with which of the following?

  1. familial adenomatous polyposis
  2. FH
  3. Li Fraumeni syndrome
  4. von Hippel-Lindau syndrome
  5. von Recklinghausen disease (type I neurofibromatosis)

Answer(s): E

Explanation:

von Recklinghausen disease (neurofibromatosis, type I), an autosomal-dominant disorder, is one of the most striking disorders that exhibits variable expressivity (phenotypic variation). Symptoms can range from the benign appearance of café au lait spots to severe disfiguring cutaneous neurofibromas, sarcomas, and gliomas. This disorder is caused by disruption in the neurofibromin gene whose protein product functions the catalysis of inactivation of the signaling protein RAS. FAP coli (choice A) is a disorder that results in the generation of numerous small polyps in the colon by the time an individual reaches age 20. Although the polyps are asymptomatic, they are a significant contributory factor to risk and likelihood of colon cancer.
This disorder is caused by mutations in the APC gene, is inherited in autosomal-dominant fashion, and its penetrance is 100% in all afflicted individuals. FH (choice B) is caused by mutations in the gene for the LDL receptor. Inheritance is autosomal dominant ith 100% penetrance. FH sufferers may be either heterozygous or homologous for a particular mutation in the receptor gene. Homozygotes exhibit grossly elevated serum cholesterol (primarily in LDLs). The elevated levels of LDLs result in their phagocytosis by macrophages. These lipidladen phagocytic cells tend to deposit within the skin and tendons, leading to xanthomas. A greater complication results from cholesterol deposition within the arteries, leading to atherosclerosis, the major contributing factor of nearly all cardiovascular diseases. LFS (choice C) is a rare form of autosomal-dominant inherited cancer caused by mutations in the tumor suppressor gene, p53. The disruption in the function of p53 leads to aberrant cell-cycle regulation and development of sarcomas, brain tumors, breast cancer, and leukemias. Cancer occurs in 50% of afflicted individuals by the time they are 30 years of age. VHL syndrome (choice D) is an inherited form of renal carcinoma that is caused by mutations in a tumor suppressor gene identified as the VHL gene.



Which of the following factors of blood coagulation is the major inhibitor of the extrinsic clotting cascade?

  1. antithrombin III
  2. high molecular weight kininogen
  3. lipoprotein-associated coagulation factor
  4. alpha-2-macroglobulin
  5. protein C

Answer(s): C

Explanation:

The major mechanism for the inhibition of the extrinsic pathway occurs at the tissue factor--factor VIIa-Ca2 +-Xa--complex. The protein, lipoprotein-associated coagulation inhibitor (LACI, formerly named anticonvertin), specifically binds to this complex. LACI is composed of three tandem protease inhibitor domains. Domain 1 binds to factor Xa and domain 2 binds to factor VIIa only in the presence of factor Xa.
Antithrombin III (choice A) is the most important of four thrombin regulatory proteins. This is because antithrombin III can also inhibit the activities of factors IXa, Xa, XIa, and XIIa. The activity of antithrombin III is potentiated in the presence of heparin. Heparin binds to a specific site on antithrombin III, producing an altered conformation of the protein, and the new conformation has a higher affinity for thrombin as well as its other substrates. This effect of heparin is the basis for its clinical use as an anticoagulant. The naturally occurring heparin activator of antithrombin III is present as heparan and heparan sulfate on the surface of vessel endothelial cells. It is this feature that controls the activation of the intrinsic coagulation cascade.
HMWK (choice B) is important for initiation of the intrinsic pathway. When prekallikrein, HMWK, factor XI, and factor XII are exposed to a negatively charged surface, they become active. This is termed the contact phase. Exposure of collagen to a vessel surface is the primary stimulus for the contact phase. In addition to antithrombin III, thrombin activity is also inhibited by alpha-2-macroglobulin (choice D). Protein C (choice E) is activated by thrombin when thrombin is bound to thrombomodulin. Active protein C functions with its cofactor, protein S, to degrade factors VIIIa and Xa.



Viewing page 76 of 171
Viewing questions 376 - 380 out of 845 questions


Post your Comments and Discuss USMLE STEP1 exam prep with other Community members:

AI Tutor AI Tutor 👋 I’m here to help!